Modulating molecular functions of p53 with small molecules

Cell Cycle

Volumn 5, Issue 22, 2006, Pages 2575-2578

  Mujtaba, Shiraz ^a   Zeng, Lei ^a   Zhou, Ming Ming ^a  

^a NEW YORK UNIVERSITY   (United States)

Author keywords

Bromodomain; CREB binding protein (CBP); Lysine acetylation; Small molecules; Tumor suppressor p53

Indexed keywords

CHROMOSOME PROTEIN; PROTEIN MDM2; PROTEIN P53; SULFONAMIDE;

DNA BINDING; DNA DAMAGE; EFFECTOR CELL; MOLECULAR INTERACTION; NONHUMAN; PROTEIN FUNCTION; REVIEW;

EID: 33751229283     PISSN: 15384101     EISSN: 15514005     Source Type: Journal    
DOI: 10.4161/cc.5.22.3464     Document Type: Review

References (45)

1. el-Deiry WS. Regulation of p53 downstream genes. Semin Cancer Biol 1998; 8:345-57.
2. Oren M. Decision making by p53: Life, death and cancer. Cell Death Differ 2003; 10:431-42.
3. Prives C, Hall PA. The p53 pathway. J Pathol 1999; 187:112-26.
4. Vogelstein B, Lane D, Levine AJ. Surfing the p53 network. Nature 2000; 408:307-10.
5. Levine AJ. p53, the cellular gatekeeper for growth and division. Cell 1997; 88:323-31.
6. Vousden KH. Apoptosis. p53 and PUMA: A deadly duo. Science 2005; 309:1685-6.
7. Giaccia AJ, Kastan MB. The complexity of p53 modulation: Emerging patterns from divergent signals. Genes Dev 1998; 12:2973-83.
8. Vousden KH. Activation of the p53 tumor suppressor protein. Biochim Biophys Acta 2002; 1602:47-59.
9. Haupt Y, Maya R, Kazaz A, Oren M. Mdm2 promotes the rapid degradation of p53. Nature 1997; 387:296-9.
10. Kubbutat MH, Jones SN, Vousden KH. Regulation of p53 stability by Mdm2. Nature 1997; 387:299-303.
11. Ahn J, Prives C. The C-terminus of p53: The more you learn the less you know. Nat Struct Biol 2001; 8:730-2.
12. Jayaraman J, Prives C. Activation of p53 sequence-specific DNA binding by short single strands of DNA requires the p53 C-terminus. Cell 1995; 81:1021-9.
13. Hupp TR, Lane DP. Allosteric activation of latent p53 tetramers. Curr Biol 1994; 4:865-75.
14. Takenaka I, Morin F, Seizinger BR, Kley N. Regulation of the sequence-specific DNA binding function of p53 by protein kinase C and protein phosphatases. J Biol Chem 1995; 270:5405-11.
15. Hupp TR, Meek DW, Midgley CA, Lane DP. Regulation of the specific DNA binding function of p53. Cell 1992; 71:875-86.
16. Hupp TR, Sparks A, Lane DP. Small peptides activate the latent sequence-specific DNA binding function of p53. Cell 1995; 83:237-45.
17. Gu W, Roeder RG. Activation of p53 sequence-specific DNA binding by acetylation of the p53 C-terminal domain. Cell 1997; 90:595-606.
18. Liu L, Scolnick DM, Trievel RC, Zhang HB, Marmorstein R, Halazonetis TD, Berger SL. p53 sites acetylated in vitro by PCAF and p300 are acetylated in vivo in response to DNA damage. Mol Cell Biol 1999; 19:1202-9.
19. Barlev NA, Liu L, Chehab NH, Mansfield K, Harris KG, Halazonetis TD, Berger SL. Acetylation of p53 activates transcription through recruitment of coactivators/histone acetyltransferases. Mol Cell 2001; 8:1243-54.
20. Ito A, Kawaguchi Y, Lai CH, Kovacs JJ, Higashimoto Y, Appella E, Yao TP. MDM2-HDAC1-mediated deacetylation of p53 is required for its degradation. Embo J 2002; 21:6236-45.
21. Luo J, Su F, Chen D, Shiloh A, Gu W. Deacetylation of p53 modulates its effect on cell growth and apoptosis. Nature 2000; 408:377-81.
22. Pearson M, Carbone R, Sebastiani C, Cioce M, Fagioli M, Saito S, Higashimoto Y, Appella E, Minucci S, Pandolfi PP, et al. PML regulates p53 acetylation and premature senescence induced by oncogenic Ras. Nature 2000; 406:207-10.
23. Grossman SR, Deato ME, Brignone C, Chan HM, Kung AL, Tagami H, Nakatani Y, Livingston DM. Polyubiquitination of p53 by a ubiquitin ligase activity of p300. Science 2003; 300:342-4.
24. Li M, Luo J, Brooks CL, Gu W. Acetylation of p53 inhibits its ubiquitination by Mdm2. J Biol Chem 2002; 277:50607-11.
25. Mujtaba S, He Y, Zeng L, Yan S, Plotnikova O, Sachchidanand, Sanchez R, Zeleznik-Le NJ, Ronai Z, Zhou MM. Structural mechanism of the bromodomain of the coactivator CBP in p53 transcriptional activation. Mol Cell 2004; 13(2):251-63.
26. Mujtaba S, He Y, Zeng L, Farooq A, Carlson JE, Ott M, Verdin E, Zhou MM. Structural basis of lysine-acetylated HIV-1 Tat recognition by PCAF bromodomain. Mol Cell 2002; 9:575-86.
27. Jeanmougin F, Wurtz JM, Le Douarin B, Chambon P, Losson R. The bromodomain revisited. Trends Biochem Sci 1997; 22:151-3.
28. Tamkun JW, Deuring R, Scott MP, Kissinger M, Pattatucci AM, Kaufman TC, Kennison JA. brahma: A regulator of Drosophila homeotic genes structurally related to the yeast transcriptional activator SNF2/SWI2. Cell 1992; 68:561-72.
29. Dhalluin C, Carlson JE, Zeng L, He C, Aggarwal AK, Zhou MM. Structure and ligand of a histone acetyltransferase bromodomain. Nature 1999; 399:491-6.
30. Zeng L, Zhou MM. Bromodomain: An acetyl-lysine binding domain. FEBS Lett 2002; 513:124-8.
31. Thut CJ, Chen JL, Klemm R, Tjian R. p53 transcriptional activation mediated by coactivators TAFII40 and TAFII60. Science 1995; 267:100-4.
32. Vassilev LT. Small-molecule antagonists of p53-MDM2 binding: Research tools and potential therapeutics. Cell Cycle 2004; 3:419-21.
33. Alluri PG, Reddy MM, Bachhawat-Sikder K, Olivos HJ, Kodadek T. Isolation of protein ligands from large peptoid libraries. J Am Chem Soc 2003; 125:13995-4004.
34. Fasan R, Dias RL, Moehle K, Zerbe O, Vrijbloed JW, Obrecht D, Robinson JA. Using a beta-hairpin to mimic an alpha-helix: Cyclic peptidomimetic inhibitors of the p53-HDM2 protein-protein interaction. Angew Chem Int Ed Engl 2004; 43:2109-12.
35. Kritzer JA, Lear JD, Hodsdon ME, Schepartz A. Helical beta-peptide inhibitors of the p53-hDM2 interaction. J Am Chem Soc 2004; 126:9468-9.
36. Kritzer JA, Zutshi R, Cheah M, Ran FA, Webman R, Wongjirad TM, Schepartz A. Miniature protein inhibitors of the p53-hDM2 interaction. Chembiochem 2006; 7:29-31.
37. Galatin PS, Abraham DJ. A nonpeptidic sulfonamide inhibits the p53-mdm2 interaction and activates p53-dependent transcription in mdm2-overexpressing cells. J Med Chem 2004; 47:4163-5.
38. Grasberger BL, Lu T, Schubert C, Parks DJ, Carver TE, Koblish HK, Cummings MD, LaFrance LV, Milkiewicz KL, Calvo RR, et al. Discovery and cocrystal structure of benzodiazepinedione HDM2 antagonists that activate p53 in cells. J Med Chem 2005; 48:909-12.
39. Parks DJ, Lafrance LV, Calvo RR, Milkiewicz KL, Gupta V, Lattanze J, Ramachandren K, Carver TE, Petrella EC, Cummings MD, et al. 1,4-Benzodiazepine- 2,5-diones as small molecule antagonists of the HDM2-p53 interaction: Discovery and SAR. Bioorg Med Chem Lett 2005; 15:765-70.
40. Vassilev LT, Vu BT, Graves B, Carvajal D, Podlaski F, Filipovic Z, Kong N, Kammlott U, Lukacs C, Klein C, et al. In vivo activation of the p53 pathway by small-molecule antagonists of MDM2. Science 2004; 303:844-8.
41. Yang Z, Yik JH, Chen R, He N, Jang MK, Ozato K, Zhou Q. Recruitment of P-TEFb for stimulation of transcriptional elongation by the bromodomain protein Brd4. Mol Cell 2005; 19:535-45.
42. Hudson BP, Martinez-Yamout MA, Dyson HJ, Wright PE. Solution structure and acetyl-lysine binding activity of the GCN5 bromodomain. J Mol Biol 2000; 304:355-70.
43. Jacobson RH, Ladurner AG, King DS, Tjian R. Structure and function of a human TAFII250 double bromodomain module. Science 2000; 288:1422-5.
44. Owen DJ, Ornaghi P, Yang JC, Lowe N, Evans PR, Ballario P, Neuhaus D, Filetici P, Travers AA. The structural basis for the recognition of acetylated histone H4 by the bromodomain of histone acetyltransferase gcn5p. Embo J 2000; 19:6141-9.
45. Sachchidanand, Resnick-Silverman L, Yan S, Mutjaba S, Liu WJ, Zeng L, Manfredi JJ, Zhou MM. Target structure-based discovery of small molecules that block human p53 and CREB binding protein association. Chem Biol 2006; 13:81-90.